CEO, Luminary Therapeutics, Inc.
Jeff is a seasoned CEO with a proven track record at profitably growing emerging companies and business divisions. He has raised over $15M in seed capital from angel investors to start four different companies which he then led to becoming profitable or acquired. Jeff got his start in Cell therapy as the Chief Operating Officer of Progenitor Cell Therapy (PCT) where he supported over 25 clinical trials in the Cell and Gene Therapy field. These trials ranged from Phase I to Phase III pivotal trials. Some highlights include: Responsible for tech transferring Kite’s T-Cell therapy out of the NIH, Novartis’ cell therapy out of UPenn and Adaptimmume’s cell therapy out of UPenn. Led B-MoGen Biotechnologies to develop TcBuster the first industry wide transposon tool for the cell therapy space. Has led Luminary Therapeutics to an approved Phase I IND for Non-Hodgkin Lymphoma with a novel ligand CAR that has three distinct antigens – directed to overcome the 25% patient relapse rates due to antigen escape. Has led OX2 Therapeutics to a Phase I clinical trial for recurrent Glioblastoma.